‹ ›
MYP_087892
← PREVIOUS NEXT → BACK
Basic Information
T1249
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Standard
39 amino acids
C233H338N56O67
Standard
Sequence
WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF
Physicochemical Analysis
4995.51 Da
4.43
-4.22
-4.45
-0.1083
-1.09
0.50
-0.09
28.84
77.69
0.1795
28990.00
28990.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
2055.96
-10.83
68.0
63.0
169.0
356.0
12.0
46.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0237764 VERIFIED: YES
Provenance & Taxonomy
not reported [other]
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Antimicrobial
PaperHIPdb: a database of experimentally validated HIV inhibiting peptides PMID23359817 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23359817/
RECORD: Rec_0269834 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral
098 virus
0.013 μg/mL
IC50
Male cynomolgus monkey blood plasma (Intravenous), in vivo; 21240 s
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0278516 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral
098-T20 virus
0.022 μg/mL
IC50
Male cynomolgus monkey blood plasma (Intravenous), in vivo; 21240 s
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0291332 VERIFIED: NO
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV gp41 fusion inhibitor
32630.0
Structure & Mods
synthetic linear peptide [Linear]
mixed L/D amino-acid peptide [Mixed]
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibitor
HIV
PaperAntiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides Evidence URLhttps://patents.google.com/patent/US7556813B2/en PatentUS 7556813 B2
RECORD: Rec_0294920 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV fusion inhibitor
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1
Monkey serum: Half-life is 5.9 h
PaperDwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. PMID:17640899 https://pubmed.ncbi.nlm.nih.gov/17640899/ PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
FIRST PREV 1 2 3 4 5 6 NEXT LAST
Showing 5 records on this page · Page 4 of 6